Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

2.

Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions

3.

Is global cancer care losing its human touch?

4.

After targeted agents, a novel bispecific in EGFR-mutant lung cancer improves PFS.

5.

FDA Approves New Bladder Cancer First-Line Standard of Care.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot